Managing Severe Symptoms and Disease Progression in the GVHD Journey

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC, and William Dale, MD, PhD, discuss why geriatric assessments are important in providing individualized care.

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.